Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.

Molecular diagnosis & therapy - 1 May 2022

Bhai Pratibha, Hsia Cyrus C, Schenkel Laila C, Hedley Benjamin D, Levy Michael A, Kerkhof Jennifer, Santos Stephanie, Stuart Alan, Lin Hanxin, Broadbent Robert, Nan Shirley, Yang Ping, Xenocostas Anargyros, Chin-Yee Ian, Sadikovic Bekim

Abstract excerpt

BACKGROUND: The use of molecular genetic biomarkers is rapidly advancing to aid diagnosis, prognosis, and clinical management of hematological disorders. We have implemented a next-generation sequencing (NGS) assay for detection of genetic variants and fusions as a frontline test for patients suspected with myeloid malignancy. In this study, we summarize the findings and assess the clinical impact in the first...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA
Share to Gene Fusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 35381971
DOI: 10.1007/s40291-022-00581-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.PMID 35381971Read ↗

Implementation of an NGS‐based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignanciesSemantic proximity Read ↗

Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.Semantic proximity Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.Semantic proximity Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasmsSemantic proximity Read ↗

Analytical Validation of an Automated Semiconductor-Based Next-Generation Sequencing Assay for Detection of DNA and RNA Alterations in Myeloid Neoplasms.Semantic proximity Read ↗

Applications of next-generation sequencing in hematologic malignancies.Semantic proximity Read ↗

Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.Semantic proximity Read ↗

Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.Semantic proximity Read ↗

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine useSemantic proximity Read ↗

The role of next-generation sequencing in hematologic malignanciesSemantic proximity Read ↗

Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.Semantic proximity Read ↗

Molecular findings in myeloid neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.